DUBLIN--(BUSINESS WIRE)--The "Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H1 2018" report has been added to ResearchAndMarkets.com's offering.
Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Gastrointestinal Stromal Tumor (GIST) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Gastrointestinal Stromal Tumor (GIST) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gastrointestinal Stromal Tumor (GIST) and features dormant and discontinued projects.
The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 2, 15, 17, 1, 7 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.
Key Topics Covered
- Introduction
- Gastrointestinal Stromal Tumor (GIST) - Overview
- Gastrointestinal Stromal Tumor (GIST) - Therapeutics Development
- Gastrointestinal Stromal Tumor (GIST) - Therapeutics Assessment
- Gastrointestinal Stromal Tumor (GIST) - Companies Involved in Therapeutics Development
- Gastrointestinal Stromal Tumor (GIST) - Drug Profiles
- Gastrointestinal Stromal Tumor (GIST) - Dormant Projects
- Gastrointestinal Stromal Tumor (GIST) - Discontinued Products
- Gastrointestinal Stromal Tumor (GIST) - Product Development Milestones
- Appendix
Companies Mentioned
- AB Science SA
- Ariad Pharmaceuticals Inc
- Arog Pharmaceuticals Inc
- ArQule Inc
- Array BioPharma Inc
- Ascentage Pharma Group Corp Ltd
- Bayer AG
- Blueprint Medicines Corp
- Boston Biomedical Inc
- Calithera Biosciences Inc
- Celldex Therapeutics
For more information about this report visit https://www.researchandmarkets.com/research/b98nwn/gastrointestinal?w=4
